

MT2023-28: A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors: PLEXI-T(TM)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- previously received at least one line of standard systemic therapy for advanced or metastatic cancer and have either progressed, recurred, or were intolerant to the previous treatment - unable to do physically strenuous activity but able to walk and carry out work of a light or sedentary nature, e.g., light house work, office work - women must not be pregnant or breastfeeding - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- known active CNS metastases - systemic steroid therapy - history of a bleeding disorder - active, uncontrolled bacterial, fungal, or viral infection - prior history or have another cancer

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), advanced cancer, cancer, metastatic cancer, solid tumors

More Information

Description: This study aims to find out if investigational new drugs, TSC-204-A0201, TSC-204- A0702 and TSC-200-A0201, can help your cancer better than the standard of care (SOC) that are currently available and accepted by medical experts as a proper treatment. T-cells are part of the immune system and develop from stem cells in the bone marrow. They help protect the body from infection and fight cancer. For this study, T-cells will be collected through a process called leukapheresis. T-cells from your leukapheresis will be used to make the study drugs specifically tailored for you and your immune system. The purpose of the study is to learn if the study drugs are safe and effective in treating your type of cancer.

Study Contact: Nathan Meyers - meye3679@umn.edu

Principal Investigator: Benjamin Manning

Phase: PHASE1

IRB Number: STUDY00019932

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.